In summary, we have demonstrated that salinomycin targets the CSC population in NSCLC and plays a role in reducing the metastatic burden and decreasing expression of ALDH, SOX2, CXCR4, and SDF-1, as well as the number of CD11b+ and F4/80+ cells. This evidence concerns the gene ITGAM and non-small cell lung carcinoma.